Submission Deadline 01/07/2028
Fiscal Capacity $50,135,013
HHS-NIH11 Grant — Key Facts
Opportunity Number PAR-25-145
Agency HHS-NIH11
Application Deadline 01/07/2028
Award Amount $50,135,013
Status Posted
Sector Health
Cost Sharing Not Required

Fiscal Parameters & Taxonomy

Authority HHS-NIH11
Status Posted

Who Can Apply

Native American tribal organizations (other than Federally recognized tribal governments) Private institutions of higher education County governments Others (see text field entitled "Additional Information on Eligibility" for clarification) Public housing authorities/Indian housing authorities Public and State controlled institutions of higher education Small businesses Special district governments Independent school districts State governments For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education

Eligibility Intelligence

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

Program Description

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

CFDA Programs

93.393 Cancer Cause and Prevention Research

Agency Contact

NIH Grants Information grantsinfo@nih.gov

✉ grantsinfo@nih.gov

📞 301-402-2541

Related Intelligence Guides

In-depth editorial guides covering this agency's programs, eligibility requirements, and application strategies.

GrantMetric Intelligence Systems — Independent federal grant intelligence platform. Not affiliated with Grants.gov, the U.S. Department of Health & Human Services, or any government agency. Grant data is sourced from the Grants.gov API for informational purposes only; always verify opportunity details directly with the funding agency before applying. Some links on this site are affiliate links — we may earn a commission at no additional cost to you. Full Disclaimer  ·  Last Reviewed: May 2026  ·  Data Methodology